There were 468 press releases posted in the last 24 hours and 429,350 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Merus kündigt Präsentation von zwei klinischen Abstracts zu Zenocutuzumab (Zeno) bei nicht-kleinzelligem Lungenkrebs (NSCLC) und Bauchspeicheldrüsenkrebs (PDAC) mit NRG1-Fusion (NRG1+) auf dem ESMO-Kongress 2023 an

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image